Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held U.S. pharmaceutical company that develops respiratory products as generic alternatives to drugs for asthma and chronic obstructive pulmonary disease (COPD). The acquisition provides Sandoz with three promising development projects targeting leading medicines in this field, as well as access to Oriel’s FreePath drug delivery technology. Oriel will be integrated as a separate development unit within Sandoz. Te...